Inhibition of human converting enzyme in vitro by a novel tripeptide analog

Hypertension. 1981 May-Jun;3(3 Pt 2):I50-3. doi: 10.1161/01.hyp.3.3_pt_2.i50.

Abstract

We have studied inhibition of homogeneous human converting enzyme by a new inhibitor, a ketomethylene derivative of the blocked tripeptide substrate, Bz-Phe-Gly-Pro (ketoACE). KetoACE inhibited the hydrolysis of Hip-His-Leu and Hip-Phe-Arg at different concentrations (I50 values were 4 X 10(-8) M and 2 X 10(-7) M, respectively). Kinetic studies indicated that ketoACE inhibits the hydrolysis of both substrates by a similar, non-competitive mechanism. At the lowest enzyme concentration tested, using 3H-Hip-Gly-Gly as substrate, the I50 of ketoACE was 6 X 10(-9) M. KetoACE protected a functional tyrosine residue in the active site of human converting enzyme from modification with N-acetylimidazole. It is proposed that there are alternate (hydrophobic) binding sites for both inhibitors and substrates in the active site of human converting enzyme. It should be possible to develop other high-affinity inhibitors of this class that bind to hydrophobic sites and do not require metal binding via a sulfhydryl group.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors*
  • Binding Sites
  • Humans
  • Kinetics
  • Oligopeptides / pharmacology*
  • Proline / analogs & derivatives*
  • Proline / pharmacology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Oligopeptides
  • Proline